Oxaliplatin and paclitaxel combination in patients with platinum- pretreated ovarian carcinoma: An investigator-originated compassionate-use experience

Annals of Oncology

Volumn 10, Issue 9, 1999, Pages 1125-1128

  Faivre, S ^e   Kalla, S ^a   Cvitkovic, E ^b   Bourdon, O ^e   Hauteville, D ^c   Dourte, L M ^c   Bensmaine M A ^a   Itzhaki, M ^a   Marty, M ^e   Extra, J M ^d  

^a CAC   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c SERVICE D ENDOCRINOLOGIE   (France)

^d INSTITUT CURIE   (France)

^e NONE

Author keywords

DACH platinum; Neurotoxicity; Salvage chemotherapy; Taxanes

Indexed keywords

OXALIPLATIN; PACLITAXEL; PLATINUM;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CROSS RESISTANCE; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 0032859533     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008334215414     Document Type: Article

References (15)

1. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334 (1): 1-6.
2. Fink D, Nebel S, Norris PS et al. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer 1998; 77 (5): 741-6.
3. Brown R, Hirst GL, Gallagher WM et al. hMLH1 expression and cellular responses of ovarian tumor cells to treatment with cytotoxic anticancer agents. Oncogene 1997; 15 (1): 45-52.
4. Extra JM, Espie M, Calvo F et al. Phase I Study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25 (4): 299-303.
5. Chollet P, Bensmaïne MA, Brienza S et al. Single-agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996; 7 (10): 1065-70.
6. Soulié P, Bensmaïne MA, Garrino C et al. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 1997; 33 (9): 1400-6.
7. Rowinsky EK. Update on the antitumor activity of paclitaxel in clinical trials. Ann Pharmacother 1994; 28 (Suppl 5): S18-22-S32-34.
8. Skou G, Mangold G, Dexter D et al. Comparison of an oxaliplatin-Taxol versus a carboplatin-Taxol regimens in the treatment of the MV-522 human lung tumor xenograft. Proc Annu Meet Am Assoc Cancer Res 1996; 37; 375 (Abstr 2558).
9. Markman M, Hoskins W. Response to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population. J Clin Oncol 1992; 10 (4): 513-4.
10. Reed E, Janik J, Bookman MA et al. High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer. J Clin Oncol 1993; 11 (11): 2118-26.
11. Wils JA, van Geuns H, Wals J et al. Efficacy of carboplatin plus primary prophylactic filgrastim (granulocyte colony stimulating factor) in relapsed ovarian cancer: A study of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg. Anti-Cancer Drugs 1997; 8 (5): 432-5.
12. Pujade-Lauraine E, Guastalla JP, Weber B et al. Efficacy and safety of the combination paclitaxel-carboplatin in patients with previously treated advanced ovarian carcinoma: A multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. Semin Oncol 1997; 24 (5, Suppl 15): S15-S35.
13. Rose PG, Fusco N, Fluellen L et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998; 16 (4): 1494-7.
14. Bertelsen K, Kaenn J, Simonsen E et al. Is Cisplatin-Taxol (PT), the standard treatment in advanced ovarian cancer? Eur J Cancer 1998; 33 (Suppl 8): S138 (Abstr 614).
15. ICON2: Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. Lancet 1998; 352 (9140): 1571-6.